Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Ready Capital Corporation due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [1][2]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Ready Capital who suffered losses between November 7, 2024, and March 2, 2025, to discuss their legal rights [1]. - A class action complaint was filed on March 6, 2025, alleging that the board made materially false and misleading statements regarding the company's business and operations [2]. Group 2: Allegations Against Ready Capital - The complaint claims that significant non-performing loans in Ready Capital's commercial real estate (CRE) portfolio were unlikely to be collectible, which was not disclosed to investors [2]. - It is alleged that Ready Capital would fully reserve these problem loans to stabilize its CRE portfolio, and this was not accurately reflected in the company's expected credit loss or valuation allowances [2]. - As a result of these undisclosed issues, the company's financial results were adversely affected, and the positive statements made by the defendants were misleading [2].

Core Viewpoint - MediaAlpha, Inc. is facing legal scrutiny due to allegations of consumer deception and misconduct related to its marketing practices, leading to a settlement with the FTC involving a $45 million fine [2]. Group 1: Legal Issues - Julie & Holleman LLP is investigating potential misconduct by MediaAlpha's directors and officers in light of recent litigation from the FTC [1]. - The FTC charged MediaAlpha with deceiving consumers into purchasing health care plans that did not deliver the promised coverage and overwhelming them with telemarketing and robocalls [2]. - MediaAlpha agreed to settle the FTC's claims by paying a fine of $45 million on August 6, 2025 [2]. Group 2: Firm Information - Julie & Holleman LLP specializes in shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations [4]. - The firm has a track record of securing hundreds of millions of dollars for aggrieved companies and their shareholders [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Hims & Hers Health, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [1][2]. Group 1: Legal Investigation - The law firm is representing long-term stockholders of Hims & Hers who held shares between April 29, 2025, and June 23, 2025, and is encouraging them to discuss their legal rights [1][3]. - A class action complaint was filed on June 25, 2025, concerning the alleged misleading statements and omissions made by the company during the class period [1][2]. Group 2: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made false statements regarding its collaboration with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for its subscribers [2]. - Specific allegations include that Hims & Hers misrepresented the approval of its compounded semaglutide products and the partnership with Novo, which purportedly misled investors and led to a significant decline in the company's stock value [2].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into potential breaches of fiduciary duties by the board members of Verint Systems Inc. regarding the proposed sale to Thoma Bravo, which is perceived to undervalue the company significantly [1][6]. Company Overview - Verint Systems Inc. has entered into a definitive merger agreement with Thoma Bravo, where shareholders will receive $20.50 in cash per share [6]. - The proposed merger price is notably lower than Verint's 52-week high of $34.80 per share, despite positive projections from Wall Street analysts regarding the company's sales and revenue growth [6]. Legal Context - Johnson Fistel, PLLP is a recognized shareholder rights law firm that represents both individual and institutional investors in derivative and class action lawsuits [3]. - The firm has a history of recovering significant amounts for clients, having secured approximately $90.725 million in 2024 for aggrieved clients [4].

Core Viewpoint - The law firm Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Guess?, Inc. to Authentic Brands Group for $16.75 per share, which is significantly lower than its 52-week high of $21.81, indicating a potentially opportunistic acquisition [1][4]. Group 1: Sale Details - Guess? has agreed to be sold for $16.75 per share in cash to Authentic Brands Group [4]. - The sale price is notably below Guess?'s 52-week high of $21.81 per share, raising concerns about the fairness of the transaction [1][4]. Group 2: Shareholder Concerns - Certain existing shareholders, including co-founders and the CEO, will roll over their shares into equity interests in the post-close entity, a benefit not extended to public stockholders [2][5]. - The sale was approved by a Special Committee of the Board, which may have conflicts of interest affecting its members [3][6]. Group 3: Investigation Focus - The investigation by Wohl & Fruchter LLP aims to determine if the Special Committee acted in the best interests of Guess? shareholders, including the independence of its members and the fairness of the sale price [7].

Core Insights - Julie & Holleman LLP is investigating the proposed $2.7 billion acquisition of Soho House & Co Inc. by a group including major stockholders and hotel company MCR, citing conflicts of interest and a belief that the $9 per share offer is undervalued [1][4] - Soho House, a global membership platform, has valuable assets despite facing challenges in recent years, positioning it for long-term success [2] - The acquisition deal is expected to close by the end of the year, involving MCR and controlling stockholders like Executive Chairman Ron Burkle and Yucaipa Companies LLC [3] Legal Concerns - Julie & Holleman is pursuing potential legal claims regarding the fairness of the acquisition deal, highlighting concerns over conflicts of interest as key insiders remain with the company while public shareholders may receive less than the company's true value [4]

Core Viewpoint - Julie & Holleman LLP is investigating the proposed acquisition of WideOpenWest, Inc. by Crestview Partners and DigitalBridge Investments, citing conflicts of interest and a belief that the acquisition price of $5.20 per share is undervalued [1][4]. Company Overview - WideOpenWest, Inc. (WOW!) is a leading broadband provider in the U.S., operating in 20 markets across the Midwest and Southeast [2]. - Wall Street analysts have set an average one-year stock price target of $5.65 per share for WOW!, with a high target of $6.50 per share [2]. Acquisition Details - On August 11, 2025, WOW! announced an agreement to be taken private at a price of $5.20 per share, with Crestview Partners, which owns 37% of WOW!'s stock, partnering with DigitalBridge to acquire the remaining shares [3]. Legal Concerns - Julie & Holleman LLP is pursuing potential legal claims regarding the fairness of the acquisition deal, highlighting concerns over conflicts of interest as key insiders remain with the company while public shareholders are offered a price below the company's true value [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Venture Global, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors related to the company's initial public offering [1][2] Group 1: Allegations Against Venture Global - The complaint alleges that Venture Global made false and/or misleading statements regarding its ability to deliver liquefied natural gas (LNG) and the development of its five liquefaction and export projects, which depended on customer contracts [2] - It is claimed that Venture Global is facing legal challenges from major clients like BP and Shell due to delays in supply contracts, impacting its business operations [2] - The allegations suggest that Venture Global's business and financial prospects were overstated, potentially misleading investors [2] Group 2: Legal Representation and Contact Information - Bragar Eagel & Squire, P.C. represents individual and institutional investors in complex litigation, including securities and derivative cases [4] - Long-term stockholders of Venture Global are encouraged to contact the firm for more information regarding the claims and their rights [3][6]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Geron Corporation due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Summary by Relevant Sections Class Action Complaint - The complaint was filed on March 14, 2025, covering a Class Period from February 28, 2024, to February 25, 2025 [1] - Allegations include that Geron's management provided misleading information regarding the launch and growth potential of Rytelo (imetelstat) [2] - The complaint claims that the management expressed confidence in addressing the unmet need for the drug while downplaying risks related to monitoring requirements and competition [2] Investigation Details - The investigation focuses on whether Geron's board of directors has breached their fiduciary duties to the company [1] - Long-term stockholders are encouraged to reach out for more information regarding their rights and the ongoing investigation [3] Law Firm Background - Bragar Eagel & Squire, P.C. is a recognized law firm that represents investors in various complex litigations [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Edwards Lifesciences Corporation due to a class action complaint related to the company's fiduciary duties and misleading revenue expectations for its TAVR platform [1][2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Edwards who held shares between February 6, 2024, and July 24, 2024, following a class action complaint filed on December 13, 2024 [1]. - The law firm is encouraging affected investors to discuss their legal rights and options [1][5]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024, significantly lowering its revenue guidance for the TAVR platform for the full fiscal year [3]. - The company attributed the decline in TAVR performance to increased pressure on hospital workflows from the growth of other structural heart therapies, including its own TMTT [3]. - Following the announcement, Edwards' stock price plummeted from $86.95 to $59.70 per share, marking a decline of approximately 31.34% in one day [4]. Group 3: Company Strategy - During the second quarter, Edwards announced three acquisitions aimed at enhancing treatments alternative to TAVR, indicating a recognition of the potential slowdown in TAVR growth [3].